Compare Deere & Company (DE) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Davita Inc — how do they compare? Deere & Company trades at $584.4 (market cap $158.09B), while Davita Inc trades at $232.01 (market cap $15.12B). The key difference: Deere & Company is far larger — about 10.5× Davita Inc's market cap, and Deere & Company pays a 1.11% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DE | DVA | |
|---|---|---|
Market Cap | $158.09B | $15.12B |
Sector | Industrials | Health |
52-Week High | $662.49 | $235.71 |
52-Week Low | $439.11 | $103.87 |
Enterprise Value | $212.91B | $27.67B |
Dividend Yield | 1.11% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
